HAITI-POC - High Accuracy Immunoassay Test at Point-of-Care

HAITI-POC - 即时护理高精度免疫分析测试

• 批准号: 131615
• 金额: $ 17.56万
• 依托单位: ORPHIDIA LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=131615
• 关键词: HAITI; POC; Accuracy; Immunoassay; Test

Biomarker assays offer robust and accurate diagnosis for some conditions but cannot be performed at the point-of-care, increasing costs to the system and inconvenience for patients. In addition, current technologies are not well-suited to the complex, multi-factor analysis needed by the next generation of assays. Orphidia proposes a ground-breaking technology that brings lab-quality tests to the point-of-care and maintains accuracy for complex tests. Orphidia will transform the process of biomarker development, significantly accelerating the uptake of new assays and increasing profitability and investment in the sector. In this project we will validate the accuracy of tests run on Orphidia's chip, confirm clinical specifications for the product and refine the commercial proposition of the system. Successful delivery will allow us to move forward with completion of the full Orphidia system, in order to enter the market one year after project-end and enable faster, better treatment for patients.

生物标志物检测为某些疾病提供了可靠和准确的诊断，但无法在护理点进行，增加了系统的成本和患者的不便。此外，目前的技术不太适合下一代测定所需的复杂的多因素分析。Orphidia提出了一项突破性的技术，将实验室质量的测试带到护理点，并保持复杂测试的准确性。Orphidia将改变生物标志物开发的过程，大大加快新检测方法的采用，并增加该行业的盈利能力和投资。在这个项目中，我们将验证在Orphidia芯片上运行的测试的准确性，确认产品的临床规格，并完善系统的商业主张。成功交付将使我们能够继续完成完整的Orphidia系统，以便在项目结束后一年进入市场，为患者提供更快，更好的治疗。